Resverlogix
Pre-Approval PRO BETASlowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 4/15/2025
Pipeline by Phase
Therapeutic Focus
Clinical Trials (11)
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Started: 11/1/2015
A Study of Apabetalone in Subjects With Long -COVID
Started: 4/15/2025
An Open-Label Study of Apabetalone in Covid Infection
Started: 1/14/2022
Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease
Started: 12/1/2009
Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
Started: 5/1/2013
The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes
Started: 11/1/2012
ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
Started: 9/1/2011
The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
Started: 8/1/2011
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Started: 11/22/2022
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
Started: 11/22/2024
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
Started: 9/1/2008